Elevation Oncology, Inc. (ELEV -0.66%), a leading oncology company specializing in the development of selective cancer therapies, has made a significant announcement today. The company has appointed Joseph Ferra, M.B.A., as its Chief Executive Officer (CEO) and Tammy Furlong, M.B.A., C.P.A., as its Chief Financial Officer (CFO). These strategic appointments are expected to strengthen Elevation Oncology's leadership team and drive innovation in the field of selective oncology therapies.

‍

CEO Appointment

Joseph Ferra, previously serving as the Interim CEO and CFO, has now officially taken on the role of CEO at Elevation Oncology. With over 20 years of experience in financial, strategic, and leadership roles in the biotechnology and pharmaceutical industry, Mr. Ferra brings a wealth of knowledge to his new position. His proven track record includes successful stints as the Chief Financial Officer of Syros Pharmaceuticals and as the Managing Director and Co-Head of Healthcare Investment Banking at JMP Securities. Mr. Ferra's educational background includes a B.S. in Chemistry with Distinction from Purdue University and an M.B.A. from The Stephen M. Ross School of Business at the University of Michigan.

‍

CEO's Vision

Expressing his excitement about the role, Mr. Ferra highlighted the significance of Elevation Oncology's Phase 1 clinical trial for EO-3021 in the United States, scheduled to commence this year. He emphasized the promising preclinical and clinical data that supports EO-3021 as a potential best-in-class antibody-drug conjugate for treating solid tumors expressing Claudin 18.2. Mr. Ferra expressed his commitment to driving growth, innovation, and improved clinical outcomes in the field of selective oncology therapies.

‍

CFO Appointment

Tammy Furlong, previously serving as the Vice President of Finance and Accounting, has been appointed as the CFO of Elevation Oncology. With more than 20 years of experience in accounting, financial reporting, and strategic management, Ms. Furlong brings a robust skill set to her new role. Her leadership experience includes positions in Fortune 500 publicly traded companies, where she focused on finance operations, global strategy, and financial transformation. Ms. Furlong holds a B.S. in Accounting from Adelphi University, an M.B.A. from Bentley University, and various certifications, including a Certified Public Accountant license in Massachusetts and a Project Management Professional certification.

‍

Board's Confidence

Steve Elms, Chairman of the Board of Directors of Elevation Oncology, expressed his delight in appointing Joe and Tammy as CEO and CFO, respectively. He emphasized their wealth of knowledge, experience, and leadership skills that make them ideal candidates for their new roles. Mr. Elms highlighted the exciting phase for Elevation Oncology as they progress EO-3021 towards clinical trials, aiming to demonstrate its potential in targeting Claudin 18.2 and improving clinical outcomes for patients.